On October 30, Hca Healthcare Inc rose 3.06% in Regular Trading, trading at $477.16, with turnover of $387 million.
The move followed stronger-than-expected quarterly results and subsequent analyst target-price increases. The company reported third-quarter revenue of $19.85 billion, up 3.6% year over year, and adjusted EPS of $7.22, above market expectations near $6.65 to $6.66. Management said full-year results are expected in the upper half of its prior guidance range, reinforcing the view that operating performance remains resilient.
Institutional follow-through also supported sentiment. Bernstein raised its target price to $471 from $426, while the broader analyst consensus target was about $473.33. Earlier coverage updates had also reflected constructive positioning on Hca Healthcare Inc after the earnings release.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments